MX2021014043A - Moduladores del receptor beta-3 adrenergico de utilidad para el tratamiento o la prevencion de trastornos relacionados con ellos. - Google Patents
Moduladores del receptor beta-3 adrenergico de utilidad para el tratamiento o la prevencion de trastornos relacionados con ellos.Info
- Publication number
- MX2021014043A MX2021014043A MX2021014043A MX2021014043A MX2021014043A MX 2021014043 A MX2021014043 A MX 2021014043A MX 2021014043 A MX2021014043 A MX 2021014043A MX 2021014043 A MX2021014043 A MX 2021014043A MX 2021014043 A MX2021014043 A MX 2021014043A
- Authority
- MX
- Mexico
- Prior art keywords
- heart failure
- heart
- failure
- left ventricular
- beta
- Prior art date
Links
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 title abstract 3
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 abstract 11
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 3
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 2
- 206010024119 Left ventricular failure Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 238000002583 angiography Methods 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000002592 echocardiography Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003709 heart valve Anatomy 0.000 abstract 1
- 231100000234 hepatic damage Toxicity 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 230000008818 liver damage Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000008816 organ damage Effects 0.000 abstract 1
- 230000033764 rhythmic process Effects 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula (Ia) y sus composiciones farmacéuticas que modulan la actividad del receptor beta-3 adrenérgico. Los compuestos de la presente invención y sus composiciones farmacéuticas se dirigen a métodos de utilidad en el tratamiento de un trastorno mediado por el receptor beta-3 adrenérgico tales como insuficiencia cardíaca; rendimiento cardíaco en insuficiencia cardíaca; mortalidad, reinfarto, y/u hospitalización en relación con insuficiencia cardíaca; insuficiencia cardíaca aguda; insuficiencia cardíaca descompensada aguda; insuficiencia cardíaca congestiva; insuficiencia cardíaca congestiva severa; daño en los órganos asociado con insuficiencia cardíaca (por ejemplo, daño o insuficiencia renal, problemas de las válvulas cardíacas, problemas del ritmo cardíaco, y/o daño hepático); insuficiencia cardíaca debida a disfunción ventricular izquierda; insuficiencia cardíaca con fracción de eyección normal; mortalidad cardiovascular después de un infarto de miocardio; mortalidad cardiovascular en pacientes con insuficiencia ventricular izquierda o disfunción ventricular izquierda; insuficiencia ventricular izquierda; disfunción ventricular izquierda; insuficiencia cardíaca de clase II en base al sistema de clasificación de la New York Heart Association (NYHA); insuficiencia cardíaca de clase III en base al sistema de clasificación de la New York Heart Association (NYHA); insuficiencia cardíaca de clase IV en base al sistema de clasificación de la New York Heart Association (NYHA); LVEF < 40% por ventriculografía de radionúclidos; LVEF =35% por ecocardiografía o angiografía ventricular de contraste; y condiciones patológicas relacionadas con ello.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346293P | 2016-06-06 | 2016-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014043A true MX2021014043A (es) | 2022-02-21 |
Family
ID=59067920
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015124A MX387995B (es) | 2016-06-06 | 2017-06-05 | Moduladores del receptor beta-3 adrenergico de utilidad para el tratamiento o la prevencion de trastornos relacionados con ellos. |
| MX2021014043A MX2021014043A (es) | 2016-06-06 | 2018-12-05 | Moduladores del receptor beta-3 adrenergico de utilidad para el tratamiento o la prevencion de trastornos relacionados con ellos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015124A MX387995B (es) | 2016-06-06 | 2017-06-05 | Moduladores del receptor beta-3 adrenergico de utilidad para el tratamiento o la prevencion de trastornos relacionados con ellos. |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US20190284200A1 (es) |
| EP (1) | EP3464292B8 (es) |
| JP (3) | JP6771246B2 (es) |
| KR (2) | KR102408272B1 (es) |
| CN (1) | CN109563103B (es) |
| AR (1) | AR108772A1 (es) |
| AU (2) | AU2017278102B2 (es) |
| CA (1) | CA3026024C (es) |
| CL (1) | CL2018003451A1 (es) |
| CO (1) | CO2019000041A2 (es) |
| CR (1) | CR20180595A (es) |
| DK (1) | DK3464292T3 (es) |
| EA (1) | EA201892817A1 (es) |
| EC (1) | ECSP19001018A (es) |
| ES (1) | ES2929737T3 (es) |
| IL (2) | IL289378B (es) |
| MA (2) | MA44037B1 (es) |
| MX (2) | MX387995B (es) |
| MY (1) | MY195982A (es) |
| NI (1) | NI201800130A (es) |
| NZ (1) | NZ749202A (es) |
| PE (1) | PE20190445A1 (es) |
| PH (1) | PH12018502550B1 (es) |
| PT (1) | PT3464292T (es) |
| SG (1) | SG11201810788QA (es) |
| TN (1) | TN2018000391A1 (es) |
| TW (2) | TWI784840B (es) |
| UA (1) | UA125120C2 (es) |
| WO (1) | WO2017214002A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| SMT201900517T1 (it) | 2017-03-20 | 2019-11-13 | Forma Therapeutics Inc | Composizioni di pirrolopirrolo come attivatori di piruvato chinasi (pkr) |
| WO2019113359A1 (en) * | 2017-12-06 | 2019-06-13 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto |
| CN113226356B (zh) | 2018-09-19 | 2025-03-04 | 诺沃挪第克健康护理股份公司 | 活化丙酮酸激酶r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| CN114615977B (zh) | 2019-09-19 | 2025-01-14 | 诺沃挪第克健康护理股份公司 | 丙酮酸激酶r(pkr)活化组合物 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| WO2023017388A1 (en) * | 2021-08-09 | 2023-02-16 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure |
| CA3230339A1 (en) * | 2021-08-26 | 2023-03-02 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor for the treatment or prevention of renal cystic disease and cardiorenal syndrome |
| WO2023057896A1 (en) * | 2021-10-06 | 2023-04-13 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
| WO2023154499A1 (en) * | 2022-02-14 | 2023-08-17 | Biogen Ma Inc. | Emopamil-binding protein inhibitors and uses thereof |
| CN114539103B (zh) * | 2022-03-21 | 2023-04-07 | 佳木斯黑龙农药有限公司 | 2-二氟乙氧基-6-三氟甲基苯磺酰氯的合成方法 |
| CN116178220A (zh) * | 2022-12-13 | 2023-05-30 | 爱斯特（成都）生物制药股份有限公司 | 一种制备(2s)-2-[[3-(甲基磺酰基l)苯氧基]甲基]环氧乙烷的方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3028340C2 (de) * | 1980-07-25 | 1987-02-05 | Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe | Amino-desoxy-1.4;3.6-dianhydro-hexit-nitrate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| US5254595A (en) | 1988-12-23 | 1993-10-19 | Elf Sanofi | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them |
| FR2751646B1 (fr) | 1996-07-23 | 1999-01-22 | Sanofi Sa | Phenoxypropanolamine a action antagoniste beta3-adrenergique |
| AU7738298A (en) | 1996-12-19 | 1998-07-15 | Agrevo Uk Limited | Chromones useful as fungicides |
| FR2780057B1 (fr) | 1998-06-18 | 2002-09-13 | Sanofi Sa | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| ATE356624T1 (de) * | 1999-12-17 | 2007-04-15 | Sanofi Aventis | Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung |
| DE20204129U1 (de) | 2002-03-15 | 2002-07-25 | Wella Ag, 64295 Darmstadt | Mittel zur Färbung von Keratinfasern mit Chinolinium-Farbstoffen |
| WO2005092860A1 (en) * | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds for the treatment of diseases |
| US20080255134A1 (en) * | 2004-11-30 | 2008-10-16 | Artesian Therapeutics, Inc. | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase |
| US8697674B2 (en) | 2004-12-29 | 2014-04-15 | Naturon, Inc. | Xanthurenic acid derivative pharmaceutical compositions and methods related thereto |
| WO2008094507A2 (en) | 2007-01-26 | 2008-08-07 | Cellicon Biotechnologies, Inc. | Novel fusion compounds |
| US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
| WO2009059225A2 (en) | 2007-11-02 | 2009-05-07 | Pain Therapeutics, Inc. | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin a |
| WO2010051476A1 (en) | 2008-10-31 | 2010-05-06 | Pain Therapeutics, Inc. | Filamin a-binding anti-inflammatory analgesic |
| EP2488177B1 (en) | 2008-10-31 | 2016-10-12 | Pain Therapeutics, Inc. | Filamin a binding anti-inflammatory and analgesic |
| US20100279997A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Analgesic that binds filamin a |
| EP2367830A1 (en) * | 2008-11-21 | 2011-09-28 | Pfizer Inc. | 1-oxa-8-azaspiro [4, 5] decane- 8 -carboxamide compounds as faah inhibitors |
| WO2011137024A1 (en) * | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| CN103140134B (zh) * | 2010-07-23 | 2015-07-29 | 默沙东公司 | 新吡咯烷衍生的β3肾上腺素能受体激动剂 |
| JP2012092038A (ja) | 2010-10-26 | 2012-05-17 | F Hoffmann La Roche Ag | 糖尿病、糖尿病関連疾患又は糖尿病性合併症の予防又は治療剤 |
| ES2716049T3 (es) | 2012-07-13 | 2019-06-07 | Pain Therapeutics Inc | Un método para inhibir la fosforilación de tau |
| WO2014012054A1 (en) | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patent |
| GB201405359D0 (en) | 2014-03-25 | 2014-05-07 | Univ Liverpool | Synthetic process |
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| WO2019113359A1 (en) * | 2017-12-06 | 2019-06-13 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto |
-
2017
- 2017-06-04 MA MA44037A patent/MA44037B1/fr unknown
- 2017-06-05 SG SG11201810788QA patent/SG11201810788QA/en unknown
- 2017-06-05 WO PCT/US2017/035867 patent/WO2017214002A1/en not_active Ceased
- 2017-06-05 MY MYPI2018002257A patent/MY195982A/en unknown
- 2017-06-05 MX MX2018015124A patent/MX387995B/es unknown
- 2017-06-05 US US16/307,830 patent/US20190284200A1/en not_active Abandoned
- 2017-06-05 CA CA3026024A patent/CA3026024C/en active Active
- 2017-06-05 IL IL289378A patent/IL289378B/en unknown
- 2017-06-05 UA UAA201900139A patent/UA125120C2/uk unknown
- 2017-06-05 NZ NZ749202A patent/NZ749202A/en not_active IP Right Cessation
- 2017-06-05 AU AU2017278102A patent/AU2017278102B2/en active Active
- 2017-06-05 KR KR1020227004041A patent/KR102408272B1/ko active Active
- 2017-06-05 KR KR1020197000005A patent/KR20190026731A/ko not_active Withdrawn
- 2017-06-05 ES ES17730638T patent/ES2929737T3/es active Active
- 2017-06-05 CR CR20180595A patent/CR20180595A/es unknown
- 2017-06-05 TN TNP/2018/000391A patent/TN2018000391A1/en unknown
- 2017-06-05 EA EA201892817A patent/EA201892817A1/ru unknown
- 2017-06-05 JP JP2019516084A patent/JP6771246B2/ja active Active
- 2017-06-05 EP EP17730638.8A patent/EP3464292B8/en active Active
- 2017-06-05 PE PE2018003180A patent/PE20190445A1/es unknown
- 2017-06-05 MA MA045150A patent/MA45150A/fr unknown
- 2017-06-05 CN CN201780047870.6A patent/CN109563103B/zh active Active
- 2017-06-05 DK DK17730638.8T patent/DK3464292T3/da active
- 2017-06-05 PH PH1/2018/502550A patent/PH12018502550B1/en unknown
- 2017-06-05 PT PT177306388T patent/PT3464292T/pt unknown
- 2017-06-06 AR ARP170101546A patent/AR108772A1/es active IP Right Grant
- 2017-06-06 TW TW110147004A patent/TWI784840B/zh active
- 2017-06-06 TW TW106118610A patent/TWI752963B/zh active
-
2018
- 2018-11-20 IL IL263148A patent/IL263148B/en unknown
- 2018-12-03 CL CL2018003451A patent/CL2018003451A1/es unknown
- 2018-12-05 MX MX2021014043A patent/MX2021014043A/es unknown
- 2018-12-05 NI NI201800130A patent/NI201800130A/es unknown
-
2019
- 2019-01-04 CO CONC2019/0000041A patent/CO2019000041A2/es unknown
- 2019-01-07 EC ECSENADI20191018A patent/ECSP19001018A/es unknown
- 2019-06-04 US US16/431,209 patent/US10479797B2/en active Active
- 2019-09-06 US US16/563,353 patent/US10662200B2/en active Active
-
2020
- 2020-05-12 US US16/872,812 patent/US10927123B2/en active Active
- 2020-09-18 JP JP2020157196A patent/JP7083087B2/ja active Active
- 2020-12-14 US US17/120,759 patent/US11560386B2/en active Active
-
2021
- 2021-07-20 AU AU2021206809A patent/AU2021206809B2/en active Active
-
2022
- 2022-04-21 JP JP2022069821A patent/JP7449329B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014043A (es) | Moduladores del receptor beta-3 adrenergico de utilidad para el tratamiento o la prevencion de trastornos relacionados con ellos. | |
| AU2016219612A1 (en) | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | |
| CO2021002768A2 (es) | Compuestos de 2,6-diaminopiridina | |
| WO2016022536A3 (en) | Inhibitors of myh7b and uses thereof | |
| Lassnig et al. | Pheochromocytoma crisis presenting with shock and tako-tsubo-like cardiomyopathy | |
| CR20210600A (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa | |
| MX2021014773A (es) | Formas de sales cristalinas de un inhibidor de cinasas. | |
| EP4570826A3 (en) | Specific binding molecules | |
| WO2017034990A8 (en) | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity | |
| JOP20180111B1 (ar) | منظمات مستقبل أدريناليني بيتا-3 مفيدة لمعالجة او الوقاية من اضطرابات مرتبطة بها | |
| WO2016023028A3 (en) | G protein-coupled receptor kinase 2 inhibitors and methods for use of the same | |
| De Oliveira Moreira et al. | Suramin attenuates dystrophin‐deficient cardiomyopathy in the mdx mouse model of duchenne muscular dystrophy | |
| WO2014145199A3 (en) | Retrograde delivery of sdf-1 for treatment of myocardial infarction | |
| Armstrong et al. | A canadian context for the acute study of clinical effectiveness of nesiritide and decompensated heart failure (ASCEND-HF) trial | |
| Madias | Decompensated chronic heart failure> Takotsubo syndrome versus Takotsubo syndrome> decompensated chronic heart failure: Two plausible inverse parallels | |
| Kurita et al. | Unique myocardial fibrosis pattern by late gadolinium enhanced magnetic resonance imaging in a patient with isolated noncompaction of the ventricular myocardium | |
| WO2022056068A8 (en) | Small molecule inhibitors of enpp1 | |
| Akram et al. | A left ventricular lipoma presenting as heart failure in a septuagenarian: a first case report | |
| Patra et al. | A Gerbode-like defect associated with Ebstein's anomaly in an adult patient | |
| WO2008069890A3 (en) | Adrenal grk2 activity as a therapeutic target for heart failure | |
| MX2020012717A (es) | Métodos y composiciones con bucindolol para el tratamiento de la fibrilación auricular. | |
| Burns et al. | PW346 The Utility and Safety of Contrast Echocardiography in Adult Congenital Heart disease | |
| Madias | Ventricular wall stress and late gadolinium enhancement in patients with Takotsubo syndrome: More data worth contemplating about | |
| Lawrence et al. | Right atrial “mass” after minimally invasive mitral valve repair with use of BioGlue | |
| Schneeweis et al. | Clinical vignette |